CO2024007225A2 - Tratamiento de trastornos hepáticos con un agonista del thr-β - Google Patents
Tratamiento de trastornos hepáticos con un agonista del thr-βInfo
- Publication number
- CO2024007225A2 CO2024007225A2 CONC2024/0007225A CO2024007225A CO2024007225A2 CO 2024007225 A2 CO2024007225 A2 CO 2024007225A2 CO 2024007225 A CO2024007225 A CO 2024007225A CO 2024007225 A2 CO2024007225 A2 CO 2024007225A2
- Authority
- CO
- Colombia
- Prior art keywords
- thr
- agonist
- treatment
- liver disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021130083 | 2021-11-11 | ||
| CN2022097426 | 2022-06-07 | ||
| PCT/CN2022/131297 WO2023083288A1 (en) | 2021-11-11 | 2022-11-11 | TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024007225A2 true CO2024007225A2 (es) | 2024-10-31 |
Family
ID=86335128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0007225A CO2024007225A2 (es) | 2021-11-11 | 2024-06-07 | Tratamiento de trastornos hepáticos con un agonista del thr-β |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240293416A1 (https=) |
| EP (1) | EP4429666A4 (https=) |
| JP (1) | JP2024544538A (https=) |
| KR (1) | KR20240101642A (https=) |
| CN (1) | CN118871113A (https=) |
| AU (1) | AU2022388507A1 (https=) |
| CA (1) | CA3238108A1 (https=) |
| CL (1) | CL2024001399A1 (https=) |
| CO (1) | CO2024007225A2 (https=) |
| IL (1) | IL312637A (https=) |
| MX (1) | MX2024005647A (https=) |
| PE (1) | PE20241327A1 (https=) |
| TW (1) | TW202332447A (https=) |
| WO (1) | WO2023083288A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2025245216A1 (en) * | 2024-05-22 | 2025-11-27 | Terns Pharmaceuticals, Inc. | Treatment of liver disorders with a thr-beta agonist |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018075650A1 (en) * | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| AR115666A1 (es) * | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
| CN111320609A (zh) * | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020228577A1 (zh) * | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| TW202128668A (zh) * | 2019-12-16 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 并環類衍生物、其製備方法及其在醫藥上的應用 |
| US20210379043A1 (en) * | 2020-05-13 | 2021-12-09 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| CN114437034A (zh) * | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
-
2022
- 2022-11-11 PE PE2024001030A patent/PE20241327A1/es unknown
- 2022-11-11 AU AU2022388507A patent/AU2022388507A1/en active Pending
- 2022-11-11 CA CA3238108A patent/CA3238108A1/en active Pending
- 2022-11-11 KR KR1020247018844A patent/KR20240101642A/ko active Pending
- 2022-11-11 WO PCT/CN2022/131297 patent/WO2023083288A1/en not_active Ceased
- 2022-11-11 EP EP22892081.5A patent/EP4429666A4/en active Pending
- 2022-11-11 MX MX2024005647A patent/MX2024005647A/es unknown
- 2022-11-11 TW TW111143222A patent/TW202332447A/zh unknown
- 2022-11-11 CN CN202280087379.7A patent/CN118871113A/zh active Pending
- 2022-11-11 IL IL312637A patent/IL312637A/en unknown
- 2022-11-11 JP JP2024527603A patent/JP2024544538A/ja active Pending
-
2024
- 2024-05-01 US US18/651,843 patent/US20240293416A1/en active Pending
- 2024-05-09 CL CL2024001399A patent/CL2024001399A1/es unknown
- 2024-06-07 CO CONC2024/0007225A patent/CO2024007225A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202332447A (zh) | 2023-08-16 |
| WO2023083288A1 (en) | 2023-05-19 |
| KR20240101642A (ko) | 2024-07-02 |
| CN118871113A (zh) | 2024-10-29 |
| CL2024001399A1 (es) | 2024-11-08 |
| EP4429666A1 (en) | 2024-09-18 |
| CA3238108A1 (en) | 2023-05-19 |
| US20240293416A1 (en) | 2024-09-05 |
| AU2022388507A1 (en) | 2024-06-20 |
| EP4429666A4 (en) | 2025-12-24 |
| JP2024544538A (ja) | 2024-12-03 |
| IL312637A (en) | 2024-07-01 |
| PE20241327A1 (es) | 2024-06-26 |
| MX2024005647A (es) | 2024-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024007225A2 (es) | Tratamiento de trastornos hepáticos con un agonista del thr-β | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| CL2025002208A1 (es) | Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas | |
| BR112022023048A2 (pt) | Tratamento de combinação de distúrbios hepáticos | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CL2020000907A1 (es) | Terapias de combinación y usos de las mismas. | |
| BR112021022363A2 (pt) | Composições e métodos para fabricação de células t | |
| PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
| CL2021002646A1 (es) | Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos | |
| CO6290650A2 (es) | Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales | |
| MX2023011853A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer. | |
| MX2022014237A (es) | Tratamiento combinado de trastornos hepáticos. | |
| CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| DOP2023000155A (es) | Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina | |
| BR112023020669A2 (pt) | Terapias de combinação para o tratamento de câncer | |
| CO2024009144A2 (es) | Inhibidores de cinasa met | |
| MX2021002761A (es) | Metodos para tratar la pancreatitis. | |
| CO2024001004A2 (es) | Compuestos de sulfonimidamida y usos de los mismos | |
| MX2022011845A (es) | Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2. | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| BR112021010856A2 (pt) | Vibegron para o tratamento de sintomas de bexiga hiperativa | |
| MX2024012368A (es) | Terapia combinada para el tratamiento del cancer | |
| EA202190504A1 (ru) | Способы лечения псориаза | |
| CL2023002236A1 (es) | Métodos para tratar la amiloidosis primaria |